Randomised Trial: One Cycle of Anthracycline-Containing Adjuvant Chemotherapy Compared with Six Cycles of CMF Treatment in Node-Positive, Hormone Receptor-Negative Breast Cancer Patients
| Autor: | Michael Gnant, B. Mlineritsch, Michael A. Fridrik, R. Kolb, Hubert Hausmaninger, Michael Seifert, Karin Haider, Michael Stierer, Ernst Kubista, Günther G. Steger, P. Steindorfer, Raimund Jakesz, H. Samonigg, G. Tschurtschenthaler, Ferdinand Ploner |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Anthracycline Adjuvant chemotherapy Breast Neoplasms Disease-Free Survival Drug Administration Schedule Breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Cyclophosphamide Neoplasm Staging Dose-Response Relationship Drug business.industry Carcinoma Ductal Breast Hematology Middle Aged medicine.disease Combined Modality Therapy Survival Rate Clinical trial Carcinoma Lobular Methotrexate Receptors Estrogen Chemotherapy Adjuvant Doxorubicin Vincristine Hormone receptor Lymphatic Metastasis Female Fluorouracil Cisplatin Receptors Progesterone business |
| Zdroj: | Oncology Research and Treatment. 26:115-119 |
| ISSN: | 2296-5262 2296-5270 |
| DOI: | 10.1159/000069831 |
| Popis: | A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progesterone receptors (ER, PgR), as compared with 6 cycles of dose-reduced CMF.Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Patients were stratified for tumour stage, nodal stage, menopausal status, type of surgery and participating centre.After a median follow-up of 100 months, neither disease-free (DFS) nor overall survival (OS) differed significantly between the two groups.Compared to 6 cycles of a non-standard low-dose CMF regimen 1 cycle of anthracycline- containing adjuvant chemotherapy failed to improve the outcome in women with stage II receptor-negative breast cancer in terms of DFS and OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|